Therapy-related acute myeloid leukemia (t-AML) usually stems from exposure of the bone
marrow to cytotoxic chemotherapy and/or radiation therapy. t-AML is usually associated with …

PURPOSE There are currently limited objective criteria to help assist physicians in
determining whether an individual patient with acute myeloid leukemia (AML) is likely to do …

This study investigates the intertwined processes of (anti-) apoptosis and cell proliferation in
myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Utilizing antibodies …

OBJECTIVE: Explore the efficacy of decitabine combined with homoharringtonine+
cytarabine+ granulocyte colony-stimulating factor (HAG) in the treatment of acute myeloid …

TP53 mutation is a frequent tumor suppressor mutation and a critical prognostic indicator
across studies in many malignant tumors including hematologic malignancies. However, the …

Background: Substantial progress in the therapeutic arsenal used to treat acute myeloid
leukemia became possible in the last decade, as a result of advances in gene editing and …

Acute myeloid leukemia (AML) is a heterogeneous disease, which typically affects older
people and is associated with poor clinical outcomes [1]. Whilst there have been significant …

Although the prognosis for childhood acute myeloid leukemia (AML) has improved over the
last decades to a survival of over 70%, still 30-40% relapse and 5-10% experience resistant …

Inhibition of tumor suppressor Protein Phosphatase 2A (PP2A) has been denoted as one of
the minimal requirements for malignant transformation of a human cell. In cancer, PP2A …